In 2024, China and Italy celebrated the 20th anniversary of their Comprehensive Strategic Partnership, and 2025 marks the first year of the implementation phase of the action plan. As exchanges between Hangzhou and Italian cities have multiplied, new opportunities for collaboration are emerging.
To further strengthen this collaboration, from May 20th to 23rd, the Hangzhou Investment Promotion Bureau, along with the Xiaoshan Economic and Technological Development Zone Innovation and Investment Promotion Bureau, Jiande Municipal Commerce Bureau, and Hong Kong WinHealth Pharma Group (WinHealth Pharma), participated in the "Hangzhou, China – Italy New Opportunities in the Healthcare Industry" promotional campaign in Rome and Milan, focusing on biopharma and related sectors. WinHealth Pharma – in representation of Hangzhou enterprises - actively participated in this event, which fostered communication and collaboration between China and Italy in the pharmaceutical and healthcare industries, further facilitated by the support of Livolsi & Partners.
During the event, the Chinese delegation visited the OpenZone Campus in Milan, a place conceived by Zambon – a multinational chemical-pharmaceutical company – for the exchange of knowledge in research and enterprise. This represented an opportunity to explore the ecosystem and engage in valuable conversations about the future of open innovation.
Group Photo of the Hangzhou European Investment Promotion Delegation with Zambon and OpenZone’s representatives.
With a patient-first philosophy, WinHealth Pharma focuses on the development, manufacturing, and commercialization of originator and innovative drugs. Leveraging its comprehensive end-to-end capabilities, experienced commercialization team, extensive commercial network, and in-depth local expertise, WinHealth Pharma has forged long-term, stable strategic partnerships with numerous global leading pharmaceutical and biotech companies.
Zcube – Zambon Research Venture, supports the growth and acceleration of innovative start-ups, with a primary focus on respiratory conditions, neurodegenerative diseases, and women’s health. Zcube, together with OpenZone and a few of its Zoners, welcomed the delegation and provided an in-depth overview of the center’s innovative projects within the Campus’ ecosystem.
The visit to Milan not only strengthened the dialogue between the biopharma industries of China and Italy, but also opened the door for deeper collaboration between WinHealth Pharma and OpenZone.
Looking ahead, both companies will continue to stay in touch for closer collaboration to drive innovation in the fields of scientific research and improve people’s quality of life to actively transform this approach into tangible opportunities.
About OpenZone
OpenZone is the campus, on the doorstep of Milan, dedicated to Health and founded on an approach geared towards open innovation. Conceived to build bridges between different competencies, languages, and worlds, OpenZone mission is to “uniquely create value in Healthcare, by fostering community, competencies and capital”. Today the campus is home to more than 30 enterprises, including some of the foremost biotechnology, pharmaceutical and advanced gene therapy companies, all with a strong penchant for innovation. OpenZone covers a surface area of more than 37,000 square meters, with the capacity to host up to 1,200 people.
OpenZone works closely with all stakeholders in the Healthcare sector, to ensure that Milan and Lombardy are increasingly recognized internationally as a territory of excellence for life sciences.
Learn more on www.openzone.it/en
About WinHealth Pharma
WinHealth Pharma is a China-based integrated pharmaceutical company with a core focus on kidney diseases and strategic expansion into hematology and other major therapeutic areas. It possesses comprehensive capabilities across the entire pharmaceutical value chain from research and development to manufacturing and commercialization. Guided by its “Patients-First” philosophy and the mission of “Advancing Health, Empowering Lives,” the company is dedicated to improving patients' quality of life through innovative therapies. By leveraging a multi-strategy-driven business model, WinHealth Pharma connects with global innovations to continuously build a diverse, differentiated, and highly competitive product portfolio. Anchoring a strong presence in China, the company is actively expanding into other Asian markets and key international regions, including Switzerland and Japan. WinHealth Pharma is committed to fostering an open and collaborative healthcare ecosystem, driving industry innovation to meet the evolving needs of patients worldwide. For more information, please visit www.winhealth.hk.